Prognostic Value of Heart-Type Fatty Acid-Binding Protein in Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.

Authors

Ahmed Elmewafy, Eyad Jamileh, Abdullah Hussain, Loay Kamel, Omar Farooq, Hany Gamal, Ibrahim Antoun

Published in

Cardiovascular therapeutics. Volume 2026. Issue 1. Pages e4836688.

Abstract

Heart-type fatty acid-binding protein (H-FABP) is rapidly released following myocardial injury, but its prognostic significance in acute coronary syndrome (ACS) remains uncertain. We evaluated the association between elevated H-FABP and adverse clinical outcomes in confirmed or suspected ACS.
PubMed, Embase, CENTRAL, Web of Science and Scopus were searched from inception to 30 August 2026 without date restriction. Studies assessing diagnostic and/or prognostic relevance of circulating H-FABP in adults with confirmed or suspected ACS were eligible. Prognostic outcomes included all-cause mortality, major adverse cardiovascular events (MACE), heart failure (HF)-related hospitalisation and recurrent myocardial infarction (MI). Risk of bias was assessed using QUIPS. Crude odds ratios (ORs) from extractable 2 × 2 event data were pooled using inverse-variance random-effects models with restricted maximum-likelihood estimation.
Twelve studies were included, with five contributing to meta-analysis. Elevated H-FABP was associated with higher odds of all-cause mortality (OR 5.68; 95% CI 3.98-8.09; I² = 30%), MACE (OR 4.56; 95% CI 1.97-10.55; I² = 47%), HF-related hospitalisation (OR 4.29; 95% CI 2.94-6.26; I² = 0%) and recurrent MI (OR 1.65; 95% CI 1.15-2.37; I² = 0%). Pooled estimates were unadjusted; seven studies were synthesised narratively.
Elevated H-FABP is associated with adverse outcomes in ACS, but current evidence does not establish independent prognostic value. Further prospective studies should determine whether H-FABP adds predictive value beyond established clinical and biochemical risk markers.

PMID:
42899423
Bibliographic data and abstract were imported from PubMed on 21 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.